To investigate the possible effects of telmisartan and losartan on cardiac function in adriamycin (ADR)-induced heart failure in rats, and to explore the changes in plasma level of angiotensin-(1-7)[Ang-(1-7)] and myocardial expression of angiotensin II type 1/2 receptors (AT 1 R / AT 2 R) and Mas receptor caused by the two drugs. Methods: Male Sprague-Dawley rats were randomly divided into 4 groups: the control group, ADR-treated heart failure group (ADR-HF), telmisartan plus ADR-treated group (Tel+ADR) and losartan plus ADR-treated group (Los+ADR). ADR was administrated (2.5 mg/kg, ip, 6 times in 2 weeks). The rats in the Tel+ADR and Los+ADR groups were treated orally with telmisartan (10 mg/kg daily po) and losartan (30 mg/kg daily), respectively, for 6 weeks. The plasma level of Ang-(1-7) was determined using ELISA. The mRNA and protein expression of myocardial Mas receptor, AT 1 R and AT 2 R were measured using RT-PCR and Western blotting, respectively. Results: ADR significantly reduced the plasma level of Ang-(1-7) and the expression of myocardial Mas receptor and myocardial AT 2 R, while significantly increased the expression of myocardial AT 1 R. Treatment with telmisartan and losartan effectively increased the plasma level of Ang-(1-7) and suppressed myocardial AT 1 R expression, but did not influence the expression of Mas receptor and AT 2 R. Conclusion: The protective effects of telmisartan and losartan in ADR-induced heart failure may be partially due to regulation of circulating Ang-(1-7) and myocardial AT 1 R expression.
Introduction
Adriamycin (ADR) is an anthracycline antibiotic commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinomas, and soft tissue sarcomas. Importantly, the use of adriamycin can cause acute and chronic side effects. The chronic side effects are represented by the development of cardiomyopathy and ultimately, irreversible congestive heart failure [1, 2] . Great effort has been expended in preventing or mitigating the cardiotoxic side effects of ADR [3] [4] [5] [6] [7] ; however, the mechanisms underlying ADR-induced heart failure are not fully understood.
The renin-angiotensin system (RAS) is one of the key regulators of blood pressure and cardiovascular disease [8] [9] [10] and involves several enzymes and receptors: renin, angiotensin II (Ang II), the Ang II type 1 receptor (AT 1 R), the Ang II type 2 receptor (AT 2 R) and the Mas receptor. Many reports have demonstrated the critical roles that these factors have in heart failure [9] . Ang II is an oligopeptide that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex, while AT 1 R and AT 2 R are the receptors for Ang II. AT 1 R mediates the major cardiovascular effects of Ang II, including vasoconstriction, increased vasopressin secretion, cardiac hypertrophy, cardiac contractility and extracellular matrix formation [9] . Conversely, effects mediated by AT 2 R include inhibition of cell growth, neuronal regeneration, cellular differentiation and possibly vasodilatation [9] . Angiotensin-(1-7) [Ang- (1) (2) (3) (4) (5) (6) (7) ] is a peptide formed from either Ang I or Ang II [9] . Ang-(1-7) is considered to be an important peptide fragment of the RAS, and it plays crucial roles that are often opposite from those of Ang II [11] . Ang-(1-7) can induce vasodilatation, diuresis and natriuresis, anti-hypertrophy, antiproliferation, anti-fibrosis and stimulate bradykinin and NO release via binding to the Mas receptor [12] . The Mas receptor is
Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure www.nature.com/aps Zong WN et al Acta Pharmacologica Sinica npg an oncogene as well as a receptor for Ang-(1-7) [13] . In a previous work, Mas receptor-deficient mice showed higher blood pressure values, impaired endothelial function, decreased NO production and lower endothelial NO synthetase expression [14] , indicating that the Ang-(1-7)/Mas receptor axis plays an important role in cardioprotective and antihypertensive effects. Importantly, Ang-(1-7) can prevent heart failure after myocardial ischemia [15] . Some recent studies have reported that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two classes of drugs that target RAS, may prevent ADR-induced cardiotoxicity [16] [17] [18] [19] . However, the underlying mechanisms are largely unclear. In the present study, we investigated the regulation of two ARBs (telmisartan and losartan) on plasma Ang-(1-7) levels and the mRNA and protein expression of the myocardial AT 1 R, AT 2 R and Mas receptors in ADR-induced heart failure. 
Materials and methods

Animals
Experimental protocol
Rats were randomly divided into four groups: (1) the control group (n=10, intraperitoneally injected an equal volume of normal saline); (2) the ADR-treated heart failure group (ADR-HF, n=20, intraperitoneally injected ADR, a 2.5 mg/kg dose administered 6 times in 2 weeks, resulting in a cumulative dose of 15 mg/kg); (3) the ADR plus telmisartan group (Tel+ADR, n=20, intraperitoneally injected ADR as in the ADR-HF group and administered telmisartan 10 mg/kg per day orally for 6 weeks, for a cumulative dose of 420 mg/kg); and (4) the ADR plus losartan group (Los+ADR, n=20, intraperitoneally injected ADR as in the ADR-HF group and administered Los 30 mg/kg per day orally for 6 weeks, for a cumulative dose of 1260 mg/kg). During the treatment period, body weights of the rats were measured every three days, and the doses of ADR, telmisartan or losartan were adjusted according to the change in body weight. The death of animals was recorded daily.
Echocardiography
Four weeks after the last injection, the cardiac function of the rats was evaluated by transthoracic echocardiography (Vivid 7, General Electric Co) with a 10-MHz linear-array transducer as reported previously [20] . Briefly, rats were weighed and anesthetized using 10% chloral hydrate intraperitoneally (30 mg/kg) and placed on a warm blanket. The cardiac longaxis and short-axis views were obtained in the 2-dimensional mode, and M-mode tracings were recorded. Left ventricular internal dimension systole (LVIDs), left ventricular internal dimension diastole (LVIDd) and left ventricular ejection fraction (LVEF) were recorded in the M-mode tracings by the same expert, and all measurements were performed by an observer blinded to the treatments. We defined heart failure in this rat model according to the cardiac function as assessed by echocardiography.
Plasma Ang-(1-7) assay After echocardiography, the abdominal aorta was carefully isolated, and 5 mL of arterial blood was collected into tubes containing disodium EDTA. Then, the plasma was obtained and stored at -80°C until use. Plasma Ang-(1-7) was assayed using an ELISA kit (Catalog No: F1763, Xitang Biotechnology Co, Ltd, Shanghai, China) with a microplate reader (Clinibio-128C). The optical density at 450 nm was obtained within 30 min. The standard curve was constructed by plotting the mean absorbance obtained for each reference standard against its concentration [21] . Using the mean absorbance value for each sample, the corresponding concentration was determined from the standard curve.
RNA isolation and RT-PCR
After blood collection, deeply anesthetized rats were sacrificed. Hearts were isolated and rinsed in saline. The cardiac ventricles were separated from the atria, weighed, cut into two segments, frozen in liquid nitrogen and stored at -70°C. Total RNA in the aorta from the four groups of rats was extracted using Trizol reagent (Invitrogen, USA) [22] . The RNA concentration was determined by the absorbance at 260 nm. The mRNA expression of the myocardial Mas receptor, AT 1 R and AT 2 R was determined by RT-PCR (TaKaRa Biotechnology Co Ltd, Dalian, China). The reaction conditions of RT-PCR were as follows: 30 °C for 10 min, 47 °C for 30 min, 99 °C for 5 min and 5 °C for 5 min. After reverse transcription, the cDNA was denatured at 94 °C for 2 min and subjected to 35 cycles of PCR at 94 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min (Mas receptor) and 35 cycles of PCR at 94 °C for 30 s, 59 °C for 30 s and 72 °C for 1 min (AT 1 R, AT 2 R, and β-actin), followed by extension at 72 °C for 7 min. The selected primers designed for Mas receptor, AT 1 R, AT 2 R, and β-actin were as follows: forward: 5'-ACTGCCGGGCGGTCATCATC-3', reverse: 5'-GGTGGA-GAAAAGCAAGGAGC-3' for Mas receptor (263 bp); forward: 5'-GCCCTGGCTGATTTATGC-3′, reverse: 5'-GGAAAGG-GAACACGAAGC-3' for AT 1 R; forward: 5'-TGGCTTGTCT-GTC CTCAT-3', reverse: 5'-AGACTTGGTCACGG GTAA-3' for AT 2 R; forward: 5'-AAGACCTGTACGCCAACACAGT-3', reverse: 5'-AGAAGCATTTGCGGTGGACGAT-3' for β-actin. Western blotting analysis Western blotting analysis was performed as described previously [23, 24] . Protein (20 μg) extracted from the heart tissues from the four groups was subjected to 10% polyacrylamide gel electrophoresis and then transferred onto PVDF membranes. The membranes were probed using primary antibodies against the Mas receptor, AT 1 R and AT 2 R (all from Santa Cruz Biotechnology, USA) overnight at 4 °C, followed by horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, USA) for 2 h at room temperature. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Kang Chen Bio-Tech, Shanghai, China) was used as the loading control. Antibody binding was visualized using the ECL system (Yuehua Medical Instrument Co Ltd, Guangdong, China), and the amount of Mas receptor, AT 1 R and AT 2 R were expressed relative to that of GAPDH [22] .
Statistical analysis
Results are presented as the mean±standard deviation (SD). Comparisons between two groups were assessed by Student′s t-test, and comparisons of three or more groups were performed using one-way ANOVA followed by LSD post-hoc using SPSS 11.5 software (Chicago, IL, USA). Statistical significance was set at P<0.05.
Results
Heart failure model Body weights were comparable among the four groups at the start of the study. However, after treatment, the weight gain was less in the ADR-HF group than in controls (304.4±19.8 g vs 408.6±12.8 g, P<0.01, Table 1, Figure 1 ). The body weights of the Tel+ADR and Los+ADR groups were higher than that of ADR-HF group (P<0.01, Table 1 , Figure 1 ), although these were still lower than that of the control (P<0.01, Table 1 , Figure 1) . No significant differences between the weights of the Tel+ADR and Los+ADR groups were observed (P>0.05, Table 1, Figure 1 ). At the end of the treatment (4 weeks after the last injection), the numbers of rats in each group were as follows:
Control, n=10; ADR-HF, n=9; Tel+ADR, n=12; and Los+ADR, n=13.
The cardiac function of the rats was tested at the end of the treatment (Figure 2 Table 1 ). No significant differences in the LVIDs, LVIDd, and LVEF between the Tel+ADR and Los+ADR groups were observed (Table 1) .
Plasma levels of Ang-(1-7)
The plasma level of Ang-(1-7) in the ADR-HF group was lower than that in the control group (4.27±2.79 ng/mL vs 10.26±2.39 ng/mL, P<0.01, Figure 3 ). Ang-(1-7) plasma levels of the Tel+ADR and Los+ADR groups were higher than that in ADR-HF group (7.16±2.13 ng/mL vs 4.27±2.79 ng/mL; 7.08±1.49 ng/mL vs 4.27±2.79 ng/mL, both P<0.05, Figure 3 ) but were still lower than that in control group (P<0.05, Figure 3) . There was no difference in plasma levels of Ang-(1-7) between the Tel+ADR and Los+ADR groups (P>0.05, Figure  3) .
Expression of the Mas receptor, AT 1 R and AT 2 R in the heart
The expression levels of the Mas receptor, AT 1 R and AT 2 R in cardiomyocytes were examined by RT-PCR analysis ( Figure  4 ) and Western blotting ( Figure 5 ). The mRNA and protein expression of the Mas receptor and AT 2 R were reduced in the ADR-HF group compared with the control group. Conversely, mRNA and protein expression of AT 1 R were increased. Treatment with telmisartan and losartan significantly suppressed the upregulation of AT 1 R but did not change the expression of 
Discussion
In this study, we showed that ADR decreased plasma Ang-(1-7) levels and myocardial Mas receptor and AT 2 R mRNA and protein expression, whereas it upregulated the myocardial mRNA and protein expression of AT 1 R. Two kinds of ARBs, telmisartan and losartan, attenuated the ADR-induced reduction of plasma Ang-(1-7) and suppressed the ADR-induced enhancement of myocardial AT 1 R expression. Telmisartan and losartan did not change the expression of the Mas receptor and AT 2 R. Ang-(1-7) is produced from Ang I and Ang II. Under physi- are similar to the plasma levels of Ang II [25] . Conversely, under some pathological conditions, eg, untreated essential hypertensive subjects, the urinary concentrations of Ang-(1-7) is lower than in normotensive controls, but chronic treatment with ARBs increases plasma levels of Ang-(1-7) 5-to 25-fold in both rats and humans [26] . Moreover, previous reports have suggested that Ang-(1-7) is cardioprotective in myocardial ischemia/reperfusion and heart remodeling after heart infarction or heat failure [27, 28] . In our study, the plasma Ang-(1-7) level was significantly lowered by ADR treatment. Surprisingly, treatment with either telmisartan or losartan resulted in increases in plasma Ang-(1-7) compared with the untreated ADR-HF group (both P<0.05). Based on the current results, we postulate that endogenous Ang-(1-7) could be a positive physiological protector for the heart, possibly mediating the beneficial effects of ARBs for ADR-induced heart failure.
AT 1 R and AT 2 R both belong to the family of G protein-coupled receptors, but they share only a 32%-34% identity at the amino acid level [9] . AT 1 R is widely distributed in the adrenal glands, kidneys, blood vessels, heart, brain, liver, bronchial tissue and other tissues [9] . After stimulation with Ang II, AT 1 R can cause vasoconstriction, Na/H 2 O reabsorption, inflammatory response, hypertrophy, hyperplasia, cell proliferation and so on [9] . It has been reported that the increase in oxidative stress coexists with AT 1 R upregulation in models of hypertension [29] . The data presented in this study showed that in the ADR-HF group, expression of the AT 1 R was upregulated compared with the control group (P<0.05). This phenomenon may be due to enhanced oxidative stress and an activated RAS localized to cardiac tissue during heart failure. In addition, in the telmisartan-or losartan-treated rat heart, expression of the AT 1 R returned to control values, suggesting that the inhibitory effect of ARBs on the AT 1 R contributes critically to their protective effect in ADR-induced heart failure.
The AT 2 R is localized in numerous embryonic and neonatal tissues, but its expression declines rapidly after birth and is then restricted to certain organs such as the adrenal glands, ovary, heart, brain, uterus, vascular endothelium, kidney and lung [9] . Stimulation of the AT 2 R can cause vasodilation, a reduced inflammatory response, apoptosis, anti-proliferation and anti-oxidative stress [9] . Previous studies demonstrated that the amount of AT 2 R was negatively correlated with LVIDd and positively correlated with LVEF, suggesting that left ventricular dysfunction was associated with decreased expression of myocardial AT 2 R protein [30] . The Mas receptor is also a G protein-coupled receptor, and it is widely expressed in some tissues [31] . Importantly, it is the receptor for Ang-(1-7) [13] . Recently, new evidence has suggested that Ang-(1-7) acts via NO/cGMP to prevent the Ang II-induced translocation of the nuclear factor of activated T cells in cardiomyocytes [32] . Moreover, in both in vitro and in vivo conditions, Mas receptordeficient mice showed impairment of cardiac functions such as hypotonia of myocardial contraction and reduction of cardiac output [13] . Our study showed that in ADR-treated rats, both the mRNA and protein expression of the AT 2 R and Mas receptor were downregulated. However, treatment with ARBs did not restore the expression of the AT 2 R and Mas, suggesting that although the decreases in the expression level of the AT 2 R and Mas receptor may be characteristics of ADR-induced heart failure, the cardio-protection of ARBs is not mediated by the AT 2 R and Mas receptor.
In summary, our results confirmed that ARBs are beneficial for ADR-induced heart failure and demonstrated that the influences of ARBs on circulating Ang-(1-7) levels and AT 1 R expression in cardiomyocytes may contribute to the cardioprotection of ARBs in this model. Our data may add new evidence to this research field and provide new mechanisms for applications of ARBs to reduce cardiotoxicity in ADR-treated patients. 
